MT Newswires
RBC Downgrades Apogee Therapeutics to Sector Perform From Outperform, Raises Price Target to $83 From $70, Keeps Speculative Risk
📈
AI Sentiment
Highly Positive
8/10
Latest updates and market news for APGE
AI Sentiment
Highly Positive
8/10
AI Sentiment
Neutral
4/10
Share this news page